Emplicure Past Earnings Performance
Past criteria checks 0/6
Emplicure's earnings have been declining at an average annual rate of -36.9%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 48.3% per year.
Key information
-36.9%
Earnings growth rate
-7.1%
EPS growth rate
Pharmaceuticals Industry Growth | 30.5% |
Revenue growth rate | 48.3% |
Return on equity | -129.7% |
Net Margin | 19,935.0% |
Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Emplicure makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 23 | 0 | -27 | 26 | 0 |
30 Jun 23 | 1 | -26 | 25 | 0 |
31 Mar 23 | 1 | -29 | 25 | 0 |
31 Dec 22 | 1 | -30 | 24 | 0 |
30 Sep 22 | 1 | -26 | 8 | 0 |
31 Mar 22 | 0 | -24 | 10 | 0 |
31 Dec 21 | 0 | -18 | 6 | 0 |
30 Sep 21 | 0 | -15 | 11 | 0 |
31 Dec 20 | 0 | -5 | 2 | 0 |
Quality Earnings: EMPLI is currently unprofitable.
Growing Profit Margin: EMPLI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if EMPLI's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare EMPLI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EMPLI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: EMPLI has a negative Return on Equity (-129.73%), as it is currently unprofitable.